Showing 651–675 of 7,717 international scientific journals
| Rank | Journal Name & ISSN | Country | WoS Quartile | CAS Division | Impact Factor | Scopus SJR | H-Index | Docs/yr | Self-Citation | Publisher | Profile |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 651 | Australian Journal of Management ISSN: 0312-8962 / 1327-2020 | 🇺🇸United States | Q3 | CAS Tier 3 | 3.1 | 0.778Q1 | — | 35 | 10% | SAGE | Profile |
| 652 | Avicenna ISSN: 2220-2749 | 🌐International | Q1 | CAS Tier 4 | 3.1 | — | — | — | N/A | Updating | Profile |
| 653 | Bulletin of the Korean Chemical Society ISSN: 0253-2964 / 1229-5949 | 🇺🇸United States | Q2 | CAS Tier 3 | 3.1 | 0.548Q2 | 49 | 242 | 17.4% | Wiley-Blackwell | Profile |
| 654 | Cancer Control ISSN: 1073-2748 / 1526-2359 | 🇺🇸United States | Q2 | CAS Tier 3 | 3.1 | 0.907Q1 | 66 | 133 | 4% | H. Lee Moffitt Cancer Center and Research Institute | Profile |
| 655 | Cell and Tissue Research ISSN: 0302-766X / 1432-0878 | 🇩🇪Germany | Q3 | CAS Tier 3 | 3.1 | 1.105Q1 | 125 | 216 | 3.1% | Springer Berlin Heidelberg | Profile |
| 656 | Cement ISSN: 2666-5492 | 🌐International | Q2 | — | 3.1 | — | — | — | N/A | Updating | Profile |
| 657 | Cerebellum ISSN: 1473-4222 / 1473-4230 | 🇺🇸United States | Q3 | CAS Tier 3 | 3.1 | 1.04Q1 | 61 | 123 | 11.1% | Springer US | Profile |
| 658 | Consumption and Society ISSN: 2752-8499 | 🌐International | Q3 | CAS Tier 2 | 3.1 | 0.632Q1 | — | — | N/A | Updating | Profile |
| 659 | Current Opinion in Nephrology and Hypertension ISSN: 1062-4821 / 1473-6543 | 🇺🇸United States | Q2 | CAS Tier 3 | 3.1 | 0.939Q1 | 86 | 78 | 0% | Lippincott Williams and Wilkins Ltd. | Profile |
| 660 | DECISION SCIENCES ISSN: 0011-7315 / 1540-5915 | 🇬🇧United Kingdom | Q2 | CAS Tier 3 | 3.1 | 1.204Q1 | — | 101 | 3.6% | Wiley-Blackwell | Profile |
| 661 | Diabetes & Vascular Disease Research ISSN: 1479-1641 | 🇬🇧United Kingdom | Q3 | CAS Tier 3 | 3.1 | 0.907Q2 | 49 | 33 | 3.6% | SAGE Publications Ltd | Profile |
| 662 | Digital Threats: Research and Practice ISSN: 2692-1626 / 2576-5337 | 🌐International | Q3 | CAS Tier 3 | 3.1 | 0.615Q1 | — | — | N/A | Updating | Profile |
| 663 | Environment and Planning D-Society & Space ISSN: 0263-7758 / 1472-3433Top Tier | 🇬🇧United Kingdom | Q3 | CAS Tier 1 | 3.1 | 1.314Q1 | — | 55 | 6.9% | SAGE | Profile |
| 664 | Environmental Microbiology Reports ISSN: 1758-2229 | 🇬🇧United Kingdom | Q3 | CAS Tier 3 | 3.1 | 0.823Q1 | 56 | 87 | 2.8% | Wiley-Blackwell | Profile |
| 665 | Epigenomics ISSN: 1750-1911 / 1750-192X | 🇬🇧United Kingdom | Q2 | CAS Tier 3 | 3.1 | 0.774Q2 | 44 | 110 | 6.7% | Future Medicine Ltd. | Profile |
| 666 | European Management Review ISSN: 1740-4754 / 1740-4762 | 🇺🇸United States | Q2 | CAS Tier 3 | 3.1 | 1.202Q1 | — | 42 | 17.6% | Wiley-Blackwell | Profile |
| 667 | FEBS Letters ISSN: 0014-5793 / 1873-3468 | 🇳🇱Netherlands | Q3 | CAS Tier 3 | 3.1 | 1.181Q1 | 238 | 193 | 3.3% | Wiley-Blackwell | Profile |
| 668 | Fibers and Polymers ISSN: 1229-9197 / 1875-0052 | 🌐South Korea | Q2 | CAS Tier 4 | 3.1 | 0.46Q2 | 43 | 414 | 9.1% | The Korean Fiber Society | Profile |
| 669 | Folia Microbiologica ISSN: 0015-5632 / 1874-9356 | 🌐Czech Republic | Q3 | CAS Tier 3 | 3.1 | 0.677Q2 | 42 | 88 | 0% | Springer Netherlands | Profile |
| 670 | Free Radical Research ISSN: 1071-5762 / 1029-2470 | 🇬🇧United Kingdom | Q3 | CAS Tier 3 | 3.1 | 0.695Q2 | 111 | 65 | 5.6% | Informa Healthcare | Profile |
| 671 | Frontiers in Blockchain ISSN: 2624-7852 | 🇨🇭Switzerland | Q3 | CAS Tier 3 | 3.1 | 0.569Q2 | — | 50 | 15.8% | Frontiers Media S.A. | Profile |
| 672 | Frontiers in Neuroergonomics ISSN: 2673-6195 | 🇨🇭Switzerland | Q2 | CAS Tier 3 | 3.1 | 0.671Q2 | — | 29 | 6.7% | Frontiers Media S.A. | Profile |
| 673 | Frontiers in Reproductive Health ISSN: 2673-3153 | 🇨🇭Switzerland | Q2 | CAS Tier 3 | 3.1 | 0.931Q1 | — | 229 | 4.3% | Frontiers Media S.A. | Profile |
| 674 | Fuel Cells ISSN: 1615-6846 / 1615-6854 | 🇩🇪Germany | Q3 | CAS Tier 3 | 3.1 | 0.495Q2 | 60 | 42 | 3.8% | John Wiley and Sons Ltd | Profile |
| 675 | Future Oncology ISSN: 1479-6694 / 1744-8301 | 🇬🇧United Kingdom | Q2 | CAS Tier 4 | 3.1 | 1.229Q1 | 60 | 390 | 3.3% | Future Medicine Ltd. | Profile |